5 results
This study will evaluate the antitumor activity of RAD001 versus placebo in patients with angiomyolipoma associated with either TSC or LAM.
This study will evaluate the antitumor activity of RAD001 versus placebo in patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC).
• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…
The primary objective of this study is to determine histological ablative efficacy by absence of vital (tumour) cells in the treated prostate zone with (multi)fibre setup in men with PCa scheduled for radical prostatectomy. The secondary objectives…
The primary objective of this study is to prove feasibility and safety of TPLA for LUTS due to BPO in healthy men. The secondary objectives are to determine functional voiding, erectile outcomes and changes on imaging.